Cormedix Inc. (CRMD) — SEC Filings
Cormedix Inc. (CRMD) — 28 SEC filings. Latest: 8-K (Apr 27, 2026). Includes 12 8-K, 6 10-Q, 3 DEF 14A.
View Cormedix Inc. on SEC EDGAR
Overview
Cormedix Inc. (CRMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 27, 2026: CorMedix Inc. filed an 8-K on April 27, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes a press release dated April 27, 2026, and various XBRL documents related to the report.
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Cormedix Inc. is neutral.
Filing Type Overview
Cormedix Inc. (CRMD) has filed 12 8-K, 6 10-Q, 3 DEF 14A, 1 8-K/A, 2 10-K, 2 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of CRMD's 23 recent filings, 1 were flagged as high-risk, 6 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $183,093,736 |
| Net Income | $149,034,859 |
| EPS | $1.97 |
| Debt-to-Equity | 1.01 |
| Cash Position | $48,493,076 |
| Operating Margin | 49.7% |
| Total Assets | $750,861,478 |
| Total Debt | $376,732,072 |
Key Executives
- Beth Zelnick Kaufman
Industry Context
CorMedix operates in the pharmaceutical sector, specifically focusing on infectious disease products. The market is characterized by high R&D costs, stringent regulatory hurdles, and significant competition from established players. Recent trends include a growing emphasis on novel antibiotics and infection prevention solutions, driven by rising rates of antimicrobial resistance and hospital-acquired infections.
Top Tags
financial-reporting (4) · 10-Q (4) · 8-k (3) · corporate-governance (3) · sec-filing (3) · quarterly-report (3) · DefenCath (2) · filing (2) · financials (2) · equity-sale (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| 8-K Document Size | 30228 | Size of the main 8-K filing document in bytes. |
| Press Release Size | 18876 | Size of the press release document in bytes. |
| Net Income | $149.0M | Increased from a $31.4M net loss in the prior year, indicating a significant financial turnaround. |
| Total Revenues | $183.1M | A substantial increase from $12.3M in the prior year, driven by DefenCath sales and Melinta acquisition. |
| Convertible Senior Notes | $144.5M | New debt incurred to finance the Melinta acquisition, impacting the liability structure. |
| Intangible Assets, net | $390.0M | Significantly increased from $1.8M, primarily due to the Melinta acquisition. |
| Goodwill | $17.5M | Recorded as a result of the Melinta acquisition, reflecting the excess of purchase consideration over net identifiable assets. |
| Cash and Cash Equivalents | $48.5M | Increased from $40.7M at year-end 2024, providing liquidity for operations. |
| Shares Outstanding | 78,789,045 | As of November 10, 2025, reflecting dilution from public offerings and acquisition-related stock issuance. |
| Diluted EPS | $1.97 | A significant improvement from a diluted EPS loss of $0.54 in the prior year. |
| Contingent Consideration | $95.6M | Long-term liability related to the Melinta acquisition, representing future potential payments. |
| Proceeds from Public Offering | $82.4M | Net proceeds from common stock sales, contributing to financing activities. |
| Additional shares for Incentive Plan | 4,312,000 | Represents potential dilution for common stockholders |
| Common shares outstanding | 78,340,257 | Baseline for voting power and dilution calculations |
| Series E preferred shares outstanding | 89,623 | Represents significant voting power (709,299 votes) |
Frequently Asked Questions
What are the latest SEC filings for Cormedix Inc. (CRMD)?
Cormedix Inc. has 28 recent SEC filings from Jan 2024 to Apr 2026, including 12 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CRMD filings?
Across 28 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cormedix Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cormedix Inc. (CRMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cormedix Inc.?
Key financial highlights from Cormedix Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CRMD?
The investment thesis for CRMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cormedix Inc.?
Key executives identified across Cormedix Inc.'s filings include Beth Zelnick Kaufman.
What are the main risk factors for Cormedix Inc. stock?
Of CRMD's 23 assessed filings, 1 were flagged high-risk, 6 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Cormedix Inc.?
Forward guidance and predictions for Cormedix Inc. are extracted from SEC filings as they are enriched.